What characterizes hyperacute and acute graft rejection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hyperacute rejection is indeed antibody mediated, making option (a) correct. Hyperacute rejection occurs immediately or within minutes to hours after transplantation when preformed antibodies in the recipient's circulation recognize antigens on the donor organ's vascular endothelium, as described in 1. This triggers complement activation, leading to rapid thrombosis, ischemia, and necrosis of the graft.

Key Points to Consider

  • Option (b) is incorrect because hyperacute rejection cannot be reversed with steroids; once initiated, it typically results in immediate graft loss requiring removal, as noted in 1.
  • Option (c) is incorrect as acute rejection is primarily T cell mediated, not B cell mediated, with T cells recognizing foreign HLA molecules and initiating cellular damage to the graft, a concept supported by the understanding of immune responses in transplantation 1.
  • Option (d) is incorrect because acute rejection typically occurs within days to weeks after transplantation, not over months, highlighting the importance of early detection and management, as discussed in 1.

Clinical Implications

Understanding these mechanisms is crucial for transplant management, as hyperacute rejection requires prevention through cross-matching before transplantation, while acute rejection can often be treated with immunosuppressive therapy if detected early, emphasizing the need for vigilant monitoring and timely intervention, as recommended in 1. The use of cardiac imaging, as suggested in 1, can play a significant role in assessing and following patients after heart transplantation, aiding in the early detection of complications such as graft rejection.

From the Research

Graft Rejection Mechanisms

  • Hyperacute rejection is indeed antibody-mediated, as stated in studies 2, 3, 4
  • Hyperacute rejection is not typically reversed with steroids, as antibody-mediated rejection does not respond to conventional anti-rejection therapy, including steroids 2
  • Acute rejection is not solely B cell mediated, as it involves both antibody-mediated and T-cell mediated mechanisms 3, 5
  • Acute rejection does not necessarily occur over a month, as it can occur at any time post-transplantation, depending on various factors such as donor-specific antibodies and immunosuppressive regimes 4, 6

Rejection Types and Mechanisms

  • Hyperacute rejection is a severe form of antibody-mediated rejection that occurs shortly after transplantation 2, 4
  • Acute antibody-mediated rejection is a significant cause of graft loss and is associated with worse graft outcomes 4, 6
  • Chronic antibody-mediated rejection is a major contributor to graft loss in the late posttransplant phase and is characterized by distinct pathologic lesions 3, 5, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pathological features of antibody-mediated rejection.

Current drug targets. Cardiovascular & haematological disorders, 2005

Research

Immune mechanisms of acute and chronic rejection.

Clinical biochemistry, 2016

Research

Acute antibody-mediated rejection in kidney transplant recipients.

Transplantation reviews (Orlando, Fla.), 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.